Evidence map›Paper›PMID 33705574›Full record

ArticleClinical pharmacology and therapeutics2021

Vaccines: Underlying Principles of Design and Testing.

Sallay Kallon, Shahryar Samir, Nilu Goonetilleke

Open access · hybridAbstract read
In one paragraph

Article in Clinical pharmacology and therapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Sallay KallonDepartment of Microbiology & Immunology, UNC-Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA.
Shahryar SamirDepartment of Microbiology & Immunology, UNC-Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA.
Nilu GoonetillekeDepartment of Microbiology & Immunology, UNC-Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA.
University of North Carolina at Chapel Hill · USUniversity of North Carolina Health Care · US

Funding

The UPMC Sexually Transmitted Infections Cooperative Research CenterU19AI084024 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI CHERPES, THOMAS L. · 2009 to 2013
$12.9M
University of North Carolina - Chlamydia Vaccine Initiative (UNC-CVI)U19AI144181 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DARVILLE, TONI · 2019 to 2023
$10.7M
Phase I therapeutic testing of viral-vectored vaccines that shift CD8+ T cell immunodominance to conserved regions of HIV-1U01AI131310 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI GOONETILLEKE, NILU · 2017 to 2023
$7.2M
NIAID NIH HHS U01 AI131310NIAID NIH HHS U19 AI084024NIAID NIH HHS U19 AI144181
6 · The paper itself

Abstract

In this paper, we review the key elements that should be considered to take a novel vaccine from the laboratory through to licensure in the modern era. This paper is divided into four sections. First, we discuss the host immune responses that we engage with vaccines. Second, we discuss how in vivo and in vitro studies can inform vaccine design. Third, we discuss different vaccine modalities that have been licensed or are in testing in humans. Last, we overview the basic principles of vaccine approvals. Throughout we provide real-world examples of vaccine development against infectious diseases, including coronavirus disease 2019 (COVID-19).

Indexed as

Adjuvants, ImmunologicDrug ApprovalDrug DesignDrug Evaluation, PreclinicalImmunity, HerdImmunity, InnatePublic HealthUnited StatesUnited States Food and Drug AdministrationVaccinesAdjuvants, ImmunologicVaccines

Identifiers

PMID33705574
PMCPMC8048882
OpenAlexW3134329910

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.